spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

NEUWAY Pharma and Cobra Biologics collaborate to develop GMP grade Engineered Protein Capsules (EPCs) manufacturing process

Cobra Biomanufacturing

Collaboration supports GLP toxicity studies and initiation of clinical development for treatment of Progressive Multifocal Leukoencephalopathy

Keele, UK and Bonn, Germany, 11 October 2016: Cobra Biologics Ltd, an international CDMO of biologics and pharmaceuticals, and NEUWAY Pharma GmbH, a biopharmaceutical company developing drugs for the treatment of severe orphan CNS diseases, announce today the conclusion of a Service Agreement to develop a manufacturing process for the production of GMP grade material of Engineered Protein Capsules (EPCs) using SF9 cells and subsequent baculovirus infection. The material will be used by NEUWAY for the conduct of GLP toxicity studies and initiation of clinical development in the treatment of Progressive Multifocal Leukoencephalopathy, a very severe neurodegenerative CNS disease. NEUWAY Pharma also uses its EPCs as a CNS Drug Delivery Platform by filling them with active drug substances.

Dr Heiko Manninga, Chief Scientific Officer (CSO) and Managing Director of NEUWAY Pharma commented: “The initiation of GMP development is an important step towards qualification of EPCs for clinical development. We are very happy that we have gained Cobra Biologics as partner for the GMP manufacturing of Engineered Protein Capsules.”

Peter Coleman, CEO Cobra Biologics commented: “We are very pleased to be manufacturing NEUWAY Pharma’s EPCs for what is a rare but serious disease, often resulting in severe disability or death. With Cobra’s 17 years of virus production experience we hope this is just the beginning of our collaboration.”

For more information visit on Neuway Pharma visit www.neuway-pharma.com and for Cobra Biologics, www.cobrabio.com
phone +44 (0)1782 714181
email philip.ridley-smith@cobrabio.com
web www.cobrabio.com
email Stephenson Building, The Science Park, Keele, ST5 5SP, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Peli BioThermal Key Speakers at CTS Europe

Peli BioThermal, the global name in temperature controlled packaging, will highlight the rise of reusable temperature controlled packaging as guest speakers at Clinical Trial Supply Europe, being held in Milan on March 13 – 14, 2019.
More info >>


White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

Industry Events

BioTrinity 2019

30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD

BioTrinity 2019 is taking place from the 30th April – 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement